Neonatal hyperbilirubinemia
Also known as: kernicterus · neonatal jaundice · phototherapy
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation
American Academy of Pediatrics (AAP) · 2022 · 2022 revision (Pediatrics 150(3):e2022058859)
The AAP's current guidance on jaundice in newborns born at 35 weeks' gestation or later. It sets out how clinicians should prevent, detect, monitor and treat elevated bilirubin, and it replaced the academy's 2004 guideline. The AAP states the guidance remains valid for practice through August 2027.
- Covers prevention, risk assessment and monitoring, phototherapy and escalation of care, and post-discharge follow-up for infants born at 35 weeks or more. source
- Issued as a revision that replaces the AAP's 2004 hyperbilirubinemia guideline. source
- AAP's topic hub notes the document contains 25 recommendations grouped around prevention, assessment, treatment, follow-up and hospital policy, and is stated to remain valid through August 2027. source
Jaundice in newborn babies under 28 days
National Institute for Health and Care Excellence (NICE), UK · 2010 · CG98, last updated 31 October 2023
NICE clinical guideline CG98 covers recognising, investigating and treating jaundice in babies in their first 28 days. Originally published in 2010, it has been amended several times, most recently in October 2023.
- Scope spans parent information, assessment of raised bilirubin, phototherapy thresholds, investigation for underlying causes, prolonged jaundice, and intravenous immunoglobulin or exchange transfusion. source
- The 2023 amendment highlights that visual assessment of jaundice is less reliable in babies with darker skin tones. source
US vs EU key differences
- Screening philosophy is opposite: the 2022 AAP guideline reconfirms universal predischarge bilirubin measurement (TSB or TcB) in every infant 35 weeks or more, whereas NICE CG98 states bilirubin should not be measured routinely in babies who are not visibly jaundiced. source
- NICE relies on visual inspection by parents, carers and clinicians as the primary screening step, with urgent measurement within 2 hours if jaundice appears in the first 24 hours and within 6 hours thereafter. source
- Version currency differs sharply: the US guideline was revised in 2022, while the NICE neonatal jaundice guideline dates to 2010. source
- The 2022 AAP revision raised phototherapy and exchange-transfusion thresholds relative to its earlier guidance to reduce overtreatment, so US thresholds now sit above the older NICE treatment threshold graphs in many infants. source
What changed recently
- EUCG98 (2010, evidence reviewed 2016) → CG98, last updated 31 October 20232023-10-31
The October 2023 update revised two recommendations: clinicians are reminded that jaundice-related skin colour change is harder to detect in babies with darker skin, and routine urine culture was withdrawn so that it is now considered only where urinary tract infection is clinically suspected.
- US2004 guideline → 2022 revision (Pediatrics 150(3):e2022058859)2022-08-05
The 2022 AAP revision raised the bilirubin thresholds for both phototherapy and exchange transfusion in infants of 35 or more weeks' gestation, on evidence that the 2004 curves led to substantial overtreatment. Studies applying the new curves retrospectively found roughly half of infants treated under the old thresholds would no longer qualify, without more severe hyperbilirubinaemia.
source ↗curation confidence 90%
See the full update feed for changes across every system.